INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,839,706 | -20.7% | 112,108 | -3.6% | 0.01% | -14.3% |
| Q2 2023 | $7,367,346 | +25.1% | 116,351 | +7.0% | 0.01% | +16.7% |
| Q1 2023 | $5,889,462 | +5.8% | 108,762 | +3.4% | 0.01% | 0.0% |
| Q4 2022 | $5,565,756 | +54.6% | 105,173 | +35.9% | 0.01% | +50.0% |
| Q3 2022 | $3,601,000 | -14.5% | 77,394 | +4.9% | 0.00% | 0.0% |
| Q2 2022 | $4,212,000 | -7.2% | 73,795 | -0.6% | 0.00% | 0.0% |
| Q1 2022 | $4,541,000 | +53.5% | 74,211 | +31.3% | 0.00% | +100.0% |
| Q4 2021 | $2,958,000 | -73.6% | 56,529 | -81.2% | 0.00% | -66.7% |
| Q3 2021 | $11,224,000 | +476.5% | 301,090 | +531.1% | 0.01% | +500.0% |
| Q2 2021 | $1,947,000 | +10.2% | 47,706 | -8.4% | 0.00% | 0.0% |
| Q1 2021 | $1,767,000 | -37.7% | 52,099 | -41.6% | 0.00% | 0.0% |
| Q4 2020 | $2,838,000 | +102.6% | 89,272 | +63.5% | 0.00% | 0.0% |
| Q3 2020 | $1,401,000 | -10.9% | 54,592 | -10.9% | 0.00% | 0.0% |
| Q2 2020 | $1,573,000 | -30.0% | 61,300 | -58.1% | 0.00% | -50.0% |
| Q1 2020 | $2,248,000 | +164.2% | 146,234 | +489.7% | 0.00% | +100.0% |
| Q4 2019 | $851,000 | +243.1% | 24,798 | -25.3% | 0.00% | – |
| Q3 2019 | $248,000 | -13.6% | 33,203 | +49.7% | 0.00% | – |
| Q2 2019 | $287,000 | +2.5% | 22,187 | -3.4% | 0.00% | – |
| Q1 2019 | $280,000 | +9.4% | 22,958 | +2.2% | 0.00% | – |
| Q4 2018 | $256,000 | -46.0% | 22,454 | +2.6% | 0.00% | – |
| Q3 2018 | $474,000 | -12.5% | 21,877 | -28.7% | 0.00% | -100.0% |
| Q2 2018 | $542,000 | -29.0% | 30,696 | -15.4% | 0.00% | 0.0% |
| Q1 2018 | $763,000 | +32.5% | 36,278 | -8.7% | 0.00% | 0.0% |
| Q4 2017 | $576,000 | -5.9% | 39,751 | +2.5% | 0.00% | 0.0% |
| Q3 2017 | $612,000 | +175.7% | 38,785 | +116.9% | 0.00% | – |
| Q2 2017 | $222,000 | -34.9% | 17,880 | -14.7% | 0.00% | – |
| Q1 2017 | $341,000 | -38.1% | 20,971 | -42.7% | 0.00% | -100.0% |
| Q4 2016 | $551,000 | +29.3% | 36,576 | +30.6% | 0.00% | – |
| Q3 2016 | $426,000 | -59.3% | 28,001 | +3.9% | 0.00% | -100.0% |
| Q2 2016 | $1,046,000 | +50.1% | 26,943 | +7.3% | 0.00% | 0.0% |
| Q1 2016 | $697,000 | +22.5% | 25,115 | +137.3% | 0.00% | 0.0% |
| Q4 2015 | $569,000 | -7.0% | 10,582 | -30.8% | 0.00% | 0.0% |
| Q3 2015 | $612,000 | +46.1% | 15,293 | +16.5% | 0.00% | – |
| Q2 2015 | $419,000 | -63.3% | 13,129 | -72.5% | 0.00% | -100.0% |
| Q1 2015 | $1,141,000 | +231.7% | 47,794 | +134.0% | 0.00% | – |
| Q2 2014 | $344,000 | -47.9% | 20,427 | -43.7% | 0.00% | -100.0% |
| Q1 2014 | $660,000 | – | 36,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |